FRANKFURT, Germany, Oct. 24, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that one year after launch, its Codex® Screening Kits are in use or evaluation in manufacturing process development at 50 pharmaceutical companies worldwide. The announcement was made at CPhI Worldwide, a global pharmaceutical ingredients convention meeting here this week.
Codex® Screening Kits were introduced in October 2010. Pharmaceutical and fine chemical companies including Merck, Roche, DSM and Dainippon Sumitomo are among the global customers using Codex® Screening Kits and Codex® Panels to reduce pharmaceutical manufacturing process development time and cost.
Codexis also said that through September 30, 2011, more than 10,000 kilograms of various enzymes used in commercial pharmaceutical intermediates production processes have been manufactured by the company's enzyme production partners. Smaller 10-100 kilogram quantities, also used in processes to make commercial pharmaceutical intermediates, have been manufactured at its Redwood City, CA facility.
"With a global network of production capabilities established, we are supporting our pharmaceutical and fine chemical customers at every scale, from clinical development to commercial production. This further demonstrates the utility of Codexis biocatalyst enzymes for the development and commercial production of pharmaceutical products," said Peter Strumph, Senior Vice President and Business Head, Pharmaceuticals.
Codexis is an industrial biotechnology company developing products that make manufacturing processes faster, cleaner and cheaper. Codexis' technology is commercialized with leading global pharmaceutical companies and is in development for advanced biofuels with Shell and for biobased chemicals. For more information, visit www.codexis.com.
This press release contains forward-looking statements relating to the utility of Codexis' biocatalyst enzymes for the development and commercial production of pharmaceutical products. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Important factors known to Codexis that could materially affect actual results include Codexis' dependence on contract manufacturers for commercial scale production of its biocatalysts. Other factors can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2011, including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
|SOURCE Codexis, Inc.|
Copyright©2010 PR Newswire.
All rights reserved